NIHR Oxford Biomedical Research Centre

Enabling translational research through partnership

MENUMENU
  • About
    • About the NIHR Oxford Biomedical Research Centre
    • NIHR Oxford BRC impact
    • Steering Committee
    • Promoting equality, diversity and inclusion in research
    • Current Vacancies
    • Stay in Touch
    • Contact Us
  • Research

        • Research Overview
        • Clinical Research Facility
        • Health Economics
        • Ethics in the NIHR Oxford BRC
        • Medical Statistics
        • Infections in Oxfordshire Database (IORD)
        • 15 Research Themes

        • Cancer
        • Cardiovascular Medicine
        • Digital Health from Hospital to Home
        • Gene and Cell Therapy
        • Genomic Medicine
        • Imaging
        • Inflammation across Tissues
        • Life-saving Vaccines
        • Metabolic Experimental Medicine
        • Modernising Medical Microbiology and Big Infection Diagnostics
        • Musculoskeletal
        • Preventive Neurology
        • Respiratory Medicine
        • Surgical Innovation, Technology and Evaluation
        • Translational Data Science
  • Patient and Public Involvement
    • For patients and the public
    • For researchers
    • More information
  • Training Hub
    • Training Hub Overview
    • Clinical Academic Pathway
    • Internships
    • Pre-doctoral Research Fellowships
    • Senior Research Fellowships
    • Research Training Bursaries
    • Doctoral Awards
    • Post-Doctoral Awards
    • PARC Programme
    • Other funding
    • Leadership Training
    • Useful Links
    • Training and Education Resources
    • Upcoming Training Events & Courses
  • Industry
    • Collaborate with Oxford BRC
    • Who Do We Work With?
    • Events
    • Further Information and Additional Resources
    • Contacts for Industry
  • Videos
  • News
  • Events

** HEALTH RESEARCH SHOWCASE THURSDAY 29 MAY 2025 **

News

You are here: Home > Cancer > Ten years of collaboration brings new hope for patients

Ten years of collaboration brings new hope for patients

9 November 2011 · Listed under Cancer

NIHR funded doctors, surgeons and scientists from the HIFU Unit (high intensity focused ultrasound), marked its official opening at the Churchill Hospital after a 10 year collaboration with the Haifu Company of China.

Mr David Cranston, Clinical Director of HIFU Unit, Prof Zhibiao Wang, President Haifu Technology Co.Ltd., Dame Fiona Caldicott (Chairman of OUH) Prof Zhu Yang, President of Chongqing Medical University

The £1.5m Oxford HIFU machine has been given on long-term loan from the Haifu Company and was recently used to treat 72 year old David Atwell, from Oxford, a retired Managing Director in the food industry.   Mr Atwell was diagnosed with a slow growing malignant kidney tumour in 2010.  In July of this year he took part in a clinical trial to test the effectiveness of the procedure and within several days was back to his usual routine of four games of tennis a week.

HIFU uses an ultrasound beam at 10,000 times the strength of imaging ultrasound, which passes harmlessly through living tissue and at the focal point the temperature rises to kill the diseased tissue. This can be achieved to a high degree of accuracy, without damaging surrounding or overlying tissues. This ability to cause targeted cell death in tissue at a distance from the ultrasound source makes HIFU an extremely attractive option for development as a non-invasive surgical tool.

HIFU machine

Mr David Cranston, Clinical Director of HIFU Unit and his colleague Professor Wu, one of the inventors of the HIFU machine in China, have been working for the last ten years with doctors, surgeons and scientists from the Oxford University Hospitals and the University of Oxford to evaluate the effectiveness  of treating tumour types such as: liver (ablation of primaries and metastases), kidney tumours, prostate cancer, musculoskeletal (soft tissue and osteosarcoma), gynaecological (uterine fibroids), and pancreas (pain palliation).

The obvious benefits of HIFU over existing forms of cancer treatment is that HIFU is non-invasive (so no surgical incision with its associated risk of infection or long post-operative rehabilitation) and non-ionising (so no limit to maximum dose, and can be repeated as often as necessary).  The advantages for patients are that their life is back to normal much more quickly with none of the side effects of drug therapy and they have no unsightly scars.

 

← Researchers trial new drug for women with hereditary breast and ovarian cancer
New treatment for lung, liver and renal tumours →

Other news

News Categories

News by Month

See all news

Subscribe to the Oxford BRC Newsletter

Keep informed about the work of the Oxford BRC by subscribing to our Mailchimp e-newsletter. It is produced several times a year and delivers news and information about upcoming events straight to your inbox.

Subscribe Now

Feedback

We’d love to hear your feedback. Please contact us at [email protected]

Oxford BRC on Social Media

  • Bluesky
  • Facebook
  • LinkedIn
  • Threads
  • Twitter
  • YouTube
  • Data Control and Privacy
  • Accessibility
  • Our Partners
  • Disclaimer
  • Contact

Copyright © 2025 NIHR Oxford Biomedical Research Centre